Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
4
×
clinical trials
4
×
deals
4
×
life sciences
national blog main
boston top stories
fda
national top stories
alexion pharmaceuticals
alnylam pharmaceuticals
boston
indiana blog main
indiana top stories
new york blog main
new york top stories
novartis
rna interference
san francisco blog main
san francisco top stories
sanofi
wisconsin blog main
wisconsin top stories
abbvie
akouos
alirocumab
allergan
alnylam pharmaceutials
amag pharmaceuticals
amgen
amunix
amyotrophic lateral sclerosis (als)
anirvan ghosh
arrowhead pharmaceuticals
astrazeneca
autoimmune disorders
biogen
bluerock therapeutics
boehringer ingelheim
boulder/denver blog main
What
deal
4
×
medicines
drug
pharma
abandoning
acquire
acquisitions
ago
agreed
alternative
announced
autoimmune
baggage
billion
bio
brings
candidate
cash
ceo
cholesterol
collabs
companies
company
compound
covid
cuts
daniel
development
dicerna
disease
expensive
fda
free
gets
gilead
gilead’s
help
interference
introduce
ipo
Language
unset
Current search:
biotech
×
deals
×
" clinical trials "
×
" boston blog main "
×
deal
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M